Recently, the Category 1 innovative drug Retagliptin Phosphate Tablets (Chinese trade name: 瑞泽唐) of Jiangsu Hengrui Pharmaceuticals Co., Ltd. is approved by China NMPA. It is indicated for improving the blood glucose control for adult patients with type 2 diabetes.

　　Retagliptin Phosphate is a dipeptidyl peptidase 4(DPP-4) inhibitor that inhibits DPP-4 to hydrolyze the incretin hormone, thereby increasing the plasma concentration of active glucagon-like peptide-1 (GLP-1) and glucose dependent insulin-like polypeptide (GIP). It increases the release of insulin in a glucose dependent manner and decreases glucagon to reduce blood glucose. The marketing of this drug provides new treatment options for adult patients with type 2 diabetes.